Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity
In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arise...
Gespeichert in:
Veröffentlicht in: | Journal of dermatology 2011-03, Vol.38 (3), p.216-221 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 221 |
---|---|
container_issue | 3 |
container_start_page | 216 |
container_title | Journal of dermatology |
container_volume | 38 |
creator | PICHLER, Werner J. DAUBNER, Barbara KAWABATA, Tom |
description | In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization. |
doi_str_mv | 10.1111/j.1346-8138.2010.01142.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907160270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>853677978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</originalsourceid><addsrcrecordid>eNqNkc1OwzAQhC0EoqXwCig3LqT4N3aQOCBoCwiBQCBuWK5jg0vaBjuB9u1JSOkJCfZia_3NrDwLQIRgH9V1NOkjQpNYICL6GNZdiBDF_cUG6K4fNkEXEsFiTCHvgJ0QJhDilCG4DTq4pnBdXfB87quX6HVZGB_MLLjSfbhyeRwNc-VNXBWRN0qXbj4Lh5H28xDittFQkZpl0bTKS1fkJsp-M9oFW1blweytzh54HA4ezi7i69vR5dnpdaxpinDMjCUQWZTohKU0s8woplNCUkasyDilqcFjzoXSFicU0zHMqFYas8RaO2aC9MBB61v4-XtlQimnLmiT52pm5lWQKeQogZjDP0nBSMJ5yhtP0ZLf__bGysK7qfJLiaBs1iAnsklbNmnLZg3yew1yUUv3V0Oq8dRka-FP7jVw0gKfLjfLfxvLq_NBc6v1cat3oTSLtV75N5lwwpl8uhnJhxtxd__EmGTkCw2spqk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853677978</pqid></control><display><type>article</type><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</creator><creatorcontrib>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</creatorcontrib><description>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/j.1346-8138.2010.01142.x</identifier><identifier>PMID: 21342222</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibiotics ; Chronic infection ; Cofactors ; Cross Reactions - immunology ; Cross-reactivity ; Cytokines ; drug hypersensitivity ; Drug Hypersensitivity - etiology ; Drug Hypersensitivity - immunology ; Drugs ; flare up ; Humans ; Hypersensitivity ; Immunosuppressive agents ; Lymphocytes T ; multiple drug hypersensitivity ; Risk factors ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology</subject><ispartof>Journal of dermatology, 2011-03, Vol.38 (3), p.216-221</ispartof><rights>2011 Japanese Dermatological Association</rights><rights>2011 Japanese Dermatological Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</citedby><cites>FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1346-8138.2010.01142.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1346-8138.2010.01142.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21342222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PICHLER, Werner J.</creatorcontrib><creatorcontrib>DAUBNER, Barbara</creatorcontrib><creatorcontrib>KAWABATA, Tom</creatorcontrib><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</description><subject>Antibiotics</subject><subject>Chronic infection</subject><subject>Cofactors</subject><subject>Cross Reactions - immunology</subject><subject>Cross-reactivity</subject><subject>Cytokines</subject><subject>drug hypersensitivity</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Drug Hypersensitivity - immunology</subject><subject>Drugs</subject><subject>flare up</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Immunosuppressive agents</subject><subject>Lymphocytes T</subject><subject>multiple drug hypersensitivity</subject><subject>Risk factors</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1OwzAQhC0EoqXwCig3LqT4N3aQOCBoCwiBQCBuWK5jg0vaBjuB9u1JSOkJCfZia_3NrDwLQIRgH9V1NOkjQpNYICL6GNZdiBDF_cUG6K4fNkEXEsFiTCHvgJ0QJhDilCG4DTq4pnBdXfB87quX6HVZGB_MLLjSfbhyeRwNc-VNXBWRN0qXbj4Lh5H28xDittFQkZpl0bTKS1fkJsp-M9oFW1blweytzh54HA4ezi7i69vR5dnpdaxpinDMjCUQWZTohKU0s8woplNCUkasyDilqcFjzoXSFicU0zHMqFYas8RaO2aC9MBB61v4-XtlQimnLmiT52pm5lWQKeQogZjDP0nBSMJ5yhtP0ZLf__bGysK7qfJLiaBs1iAnsklbNmnLZg3yew1yUUv3V0Oq8dRka-FP7jVw0gKfLjfLfxvLq_NBc6v1cat3oTSLtV75N5lwwpl8uhnJhxtxd__EmGTkCw2spqk</recordid><startdate>201103</startdate><enddate>201103</enddate><creator>PICHLER, Werner J.</creator><creator>DAUBNER, Barbara</creator><creator>KAWABATA, Tom</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201103</creationdate><title>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</title><author>PICHLER, Werner J. ; DAUBNER, Barbara ; KAWABATA, Tom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4912-5ef301f16c6594df5ea5c933953f8d7449e2b778acf26424b0d4cac256fffb583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibiotics</topic><topic>Chronic infection</topic><topic>Cofactors</topic><topic>Cross Reactions - immunology</topic><topic>Cross-reactivity</topic><topic>Cytokines</topic><topic>drug hypersensitivity</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Drug Hypersensitivity - immunology</topic><topic>Drugs</topic><topic>flare up</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Immunosuppressive agents</topic><topic>Lymphocytes T</topic><topic>multiple drug hypersensitivity</topic><topic>Risk factors</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PICHLER, Werner J.</creatorcontrib><creatorcontrib>DAUBNER, Barbara</creatorcontrib><creatorcontrib>KAWABATA, Tom</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PICHLER, Werner J.</au><au>DAUBNER, Barbara</au><au>KAWABATA, Tom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2011-03</date><risdate>2011</risdate><volume>38</volume><issue>3</issue><spage>216</spage><epage>221</epage><pages>216-221</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>In drug hypersensitivity, change of drug treatment and continuation with a new drug may result in reappearance of drug hypersensitivity symptoms. This is not uncommon in patients with chronic infections requiring continued and long‐lasting antibiotic treatments. For the clinician, the question arises whether these symptoms are due to cross‐reactivity, are due to a new sensitization or are a reflection of a multiple drug hypersensitivity syndrome. Based on the p‐i concept (pharmacological interaction with immune receptors), we propose that the efficient stimulation of T cells by a drug is the sum of drug–T‐cell receptor affinity and readiness of the T cell to react, and therefore not constant. It heavily depends on the state of underlying immune activation. Consequently, drug hypersensitivity diseases, which go along with massive immune stimulations and often high serum cytokine values, are themselves risk factors for further drug hypersensitivity. The immune stimulation during drug hypersensitivity may, similar to generalized virus infections, lower the threshold of T‐cell reactivity to drugs and cause rapid appearance of drug hypersensitivity symptoms to the second drug. We call the second hypersensitivity reaction a “flare‐up” reaction; this is clinically important, as in most cases the second drug may be tolerated again, if the cofactors are missing. Moreover, the second treatment is often too short to cause a relevant sensitization.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21342222</pmid><doi>10.1111/j.1346-8138.2010.01142.x</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0385-2407 |
ispartof | Journal of dermatology, 2011-03, Vol.38 (3), p.216-221 |
issn | 0385-2407 1346-8138 |
language | eng |
recordid | cdi_proquest_miscellaneous_907160270 |
source | MEDLINE; Wiley Online Library All Journals |
subjects | Antibiotics Chronic infection Cofactors Cross Reactions - immunology Cross-reactivity Cytokines drug hypersensitivity Drug Hypersensitivity - etiology Drug Hypersensitivity - immunology Drugs flare up Humans Hypersensitivity Immunosuppressive agents Lymphocytes T multiple drug hypersensitivity Risk factors T-Lymphocytes - drug effects T-Lymphocytes - immunology |
title | Drug hypersensitivity: Flare-up reactions, cross-reactivity and multiple drug hypersensitivity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A29%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20hypersensitivity:%20Flare-up%20reactions,%20cross-reactivity%20and%20multiple%20drug%20hypersensitivity&rft.jtitle=Journal%20of%20dermatology&rft.au=PICHLER,%20Werner%20J.&rft.date=2011-03&rft.volume=38&rft.issue=3&rft.spage=216&rft.epage=221&rft.pages=216-221&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/j.1346-8138.2010.01142.x&rft_dat=%3Cproquest_cross%3E853677978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853677978&rft_id=info:pmid/21342222&rfr_iscdi=true |